SEPTEMBER 8, 2014


NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

HEAD AND NECK
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Aug 25. pii: JCO.2013.53.5633. [Epub ahead of print] PMID: 25154822. Read more.

Publications Reminders
Please note the following upcoming abstract submission deadline dates:

Upcoming abstract submission deadlines
Gastrointestinal Cancers Symposium (ASCO/ASTRO/SSO/AGA), abstract submission deadline, Sept 16, 2014; late-breaking deadline, Nov 20, 2014, for 2015 meeting in San Francisco. 

SSO abstract submission deadline Sept 26, 2014, for 2015 meeting in Houston.

NSABP B-55/BIG 6-13 Investigator Letter and Slides
A letter from the Study Chairs detailing the strategies for identifying and accruing patients to the OlympiA trial and a slide set for the study are available on the CTSU and NSABP websites.


Education/Training:

Vision Tree Webinar - NRG Oncology Research Associates working on RTOG 0938, 0924, and 0920 can find the VTOC Webinar Training Series schedule and registration on the legacy RTOG website under Research Associates – Education/Training. The next session is scheduled for September 10, 2014 at 2 pm ET/ 1 pm CT / Noon MT / 11 am PT. Space is limited so register now and reserve your seat.
 

Closures

GYN
GOG-9924 Closed to patient entry effective July 12, 2014. Met accrual goal.

Amendments And Updates

BREAST
NSABP B-55/BIG 6-13
Amendment #1, NCI Version Date: July 22, 2014. The amended protocol and related documents can be found on the CTSU website.

GYN
GOG-0274/RTOG 1174 September 2014 Outback Newsletter has been posted.

LUNG
RTOG 1306

NRG Oncology has received an Action Letter for crizotinib

Accrual of new patients must be suspended until the IRB of record has reviewed and approved a CTEP-approved amendment created in response to this Action Letter. This amendment can undergo expedited approval at the discretion of the IRB Chair/designee as explained on the first page of the Action Letter.

Patients currently on study may continue on study provided they are informed of the new and/or modified risk information. This information should be communicated to patients already enrolled on study without waiting for IRB review/approval since this information represents a significant new finding(s) that developed during the course of the research that may relate to a patient’s willingness to continue participation and per the Office for Human Research Protections, the regulations do not require IRB review and approval of statements describing such significant new findings before they are provided to already enrolled patients. Documentation of their informed consent should be carried out according to local IRB requirements.

OTHER PROTOCOL NOTICES

RTOG 1010 Accrual
The Current Accrual listed on the RTOG Website on the Protocol Information Page for RTOG 1010 reflects the total accrual to STEP 1 (HER2 screening). This study will continue to accrue until 160 cases have completed STEP 2 registration. The current accrual to RTOG 1010 - STEP 2 registration is 147 as of 8/31/2014. Please continue to screen your patients for this very important study and we appreciate all of your efforts.
Drug Safety Reports
Safety updates have been issued for GOG legacy studies. For details, please see the GOG Weekly Mailing page.

Safety updates have been issued for NSABP legacy studies. For details, please see the NSABP Member's Area page.

Updated Investigator's Brochures
Updated Investigator's Brochures have been issued for NSABP B-55/BIG 6-13.
 

ASTRO Annual Meeting
The ASTRO Annual Meeting takes place Sept 14-17, 2014, in San Francisco, CA.

View NRG Oncology’s scientific presentations at ASTRO.

Visit the ASTRO Annual Meeting page for upcoming scientific meetings.